PGT research workflow solutions
PGT research workflows differ in how much of the process needs to be integrated. For labs focused on PGT-A and copy number analysis, an end-to-end NGS workflow can simplify the path from embryo biopsy sample through sequencing and analysis. For workflows that use other downstream methods, standalone whole genome amplification can serve as the front-end step before CNV analysis, STR genotyping, targeted enrichment, sequencing, or other genomic approaches.
PG-Seq Rapid v2 for PGT-A and copy number variation analysis
PG-Seq™ Rapid v2 is an NGS-based workflow for PGT-A and copy number variation analysis from embryo biopsy research samples. The kit brings together cell lysis, whole genome amplification, indexing, and library generation in a protocol designed to support chromosome-level and segmental copy number assessment.
PG-Seq indexing primers are used as part of the workflow and selected based on sample volume and multiplexing strategy. The 8 nt indexing format supports sample volumes that fit within a 96-index set, while the 12 nt indexing format expands available barcode capacity up to 384 indexes for higher-throughput needs.
Downstream analysis is supported through PG-Find™ software for aneuploidy and copy number variant analysis. Separately, mtDNA-based sample monitoring with mtDetect™ can help identify potential sample swaps, mislabeling, and external DNA contamination.
For labs processing higher sample volumes, automation can also support more consistent PGT-A sample preparation and reduce manual pipetting burden. Learn more about automation in routine PGT-A workflows.
DOPLify WGA V2 for PGT research applications
DOPLify® WGA V2 supports PGT research workflows where whole genome amplification is needed before a separate downstream analysis method. Instead of functioning as a complete PGT-A/CNV workflow, the kit serves as an upstream amplification step for workflows that require amplified embryo biopsy DNA before additional genomic analysis.
This can support downstream methods such as CNV analysis, STR genotyping, targeted enrichment, sequencing, or other PGT research approaches. In this context, the value of WGA is not simply generating more DNA. It helps prepare limited genomic material for downstream workflows where genome representation, assay compatibility, and data quality all matter.
Featured resources
FAQs
-
How is PGT-A different from copy number variation analysis?
PGT-A research is focused on chromosome copy number status, including whole chromosome gains and losses. Copy number variation analysis can also include sub-chromosomal gains and losses, sometimes referred to as segmental abnormalities. For NGS-based workflows, the ability to assess these changes depends on genome amplification quality, sequencing performance, and downstream analysis methods.
-
Why does whole genome amplification matter in PGT research workflows?
Embryo biopsy samples contain limited genomic material, so whole genome amplification is often needed before downstream analysis can be performed. The amplification step can influence genome representation, copy number noise, assay compatibility, and the quality of data generated for downstream sequencing or other genomic methods.
-
Why is sample traceability important in PGT workflows?
PGT workflows often involve limited sample material, multiple processing steps, and careful sample tracking across plates or runs. Sample traceability approaches can help identify issues such as sample swaps, mislabeling, or external DNA contamination before downstream results are interpreted.
-
What should labs consider when scaling PGT-A workflows?
As sample volume increases, labs may need to evaluate indexing capacity, sequencing run planning, automation compatibility, sample tracking, plate setup, and analysis consistency. Higher-throughput workflows benefit from planning these elements together rather than treating sample prep, indexing, sequencing, and analysis as separate decisions.
